Concord Drugs Ltd — Results, 23-05-2025: Result

Concord Drugs Limited has announced a board meeting on which approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2025. The company reported consolidated revenue of Rs. 45.25 Cr with a profit before tax of Rs. 0.69 Cr, while standalone revenue was Rs. 36.94 Cr with a profit before tax of Rs. 0.64 Cr. Earnings per share stood at Rs. 0.47 (consolidated) and Rs. 0.42 (standalone). The auditors issued an unmodified opinion but highlighted long outstanding trade receivables of Rs. 4.14 Cr over two years without provision, and balances pending confirmation and reconciliation.